
Penpulimab & Chemo: A New First-Line Option for Nasopharyngeal Cancer
In April 2025, the FDA granted approval to the combination of penpulimab plus cisplatin or carboplatin and gemcitabine for the first-line treatment of adult patients with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC).1 The …